BRTX stock was up over 200% in morning trade on January 3, 2020. We first alerted you to this stock a couple of weeks ago here.
Back on December 16, 2019, BioRestorative Therapies (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is “the world’s largest technical professional organization for the advancement of technology.” You can read the story here: https://pulse.embs.org/november-2019/stem-cell-therapies-low-back-pain/
The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Company’s lead therapeutic candidate for chronic lumbar disc disease. “Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution,” explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patient’s bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. “We are enriching the cells to be able to survive in this harsh environment,” says Silva.
In addition to BRTX-100, the magazine article also highlights BioRestorative’s other research pursuit, its ThermoStem® program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.
Personally I would avoid this stock as it has continued to downtrend even after the article hyping its pursuits. OTC stocks are risky, but biotechnology OTC stocks are downright stupid to play in most cases IMO, but hey, YOLO dudes!